Things You Should Know

What does air and water purification really address?

Air and water purification refers to reducing harmful contaminants before people breathe them in or drink them. In air, this may include particulate matter (PM2.5, fine particles 2.5 micrometers or smaller; PM10, particles 10 micrometers or smaller), volatile organic compounds (TVOC, total volatile organic compounds), and combustion gases. In water, it may include persistent chemicals such as per- and polyfluoroalkyl substances (PFAS) and byproducts such as bromate.

For longevity, the topic matters because long-term exposure to polluted air is associated in human epidemiology with higher mortality, lower lung function, and chronic respiratory burden. Water contaminants raise different concerns. Human observational studies link some PFAS exposures with higher cancer risk, altered cholesterol, liver enzyme changes, reduced vaccine response in children, and pregnancy-related complications, although much PFAS evidence also comes from animal toxicology and the strength of evidence varies by compound.

A basic distinction is prevention versus cleanup. Pollution prevention reduces emissions at the source, while purification removes contaminants after release. Both approaches may support healthier aging, but they are not interchangeable. The scientific literature supports the value of lowering exposure, yet direct lifespan gains are rarely measured in purification studies themselves.

Which core terms help explain how purification works?

Several terms make this topic easier to understand. Indoor Air Quality (IAQ) means the condition of air inside buildings as it affects comfort and health. Mechanical ventilation replaces indoor air with cleaner air. Heating, Ventilation and Air Conditioning (HVAC) systems move, filter, and condition indoor air. Air Changes per Hour (ACH) describes how often room air is replaced each hour. Carbon Dioxide (CO2) is often used as an indicator of how well a space is ventilated, not as a full measure of all pollutants.

Filtration terms also matter. High-Efficiency Particulate Air (HEPA) filters are designed to capture very small airborne particles. Minimum Efficiency Reporting Value (MERV) rates how well many Heating, Ventilation and Air Conditioning (HVAC) filters remove particles across size ranges. Higher-rated filters may remove more particles, but performance depends on the system and particle size.

For water, adsorption means pollutants stick to a material surface, such as activated carbon. Bromate is a water contaminant of concern because it is carcinogenic. Per- and polyfluoroalkyl substances (PFAS) are persistent synthetic chemicals that can remain in water and the body for long periods. These definitions help separate measured removal performance from proven human health benefit.

Why is this relevant to healthy aging and longevity?

Air and water purification relates to longevity because it aims to lower repeated exposure to contaminants that may accumulate harm over years. Human evidence is strongest for the general health burden of air pollution, especially fine particulate matter. Long-term exposure to low concentrations of particulate matter (PM, airborne particles) has been associated with death rates, bronchitis, and reduced lung function in epidemiologic research. That does not mean every purifier extends life, but lowering exposure is biologically and publicly relevant.

Indoor studies add a practical layer. In one human observational monitoring study from a dentistry clinic, mechanical ventilation and portable purifiers improved Indoor Air Quality (IAQ) measures, including particulate matter (PM2.5, particles 2.5 micrometers or smaller; PM10, particles 10 micrometers or smaller), Carbon Dioxide (CO2), and partly total volatile organic compounds (TVOC). However, that study did not measure disease events, aging markers, or survival.

Water purification matters for a similar reason. Human studies suggest some contaminants, such as per- and polyfluoroalkyl substances (PFAS), are associated with adverse health outcomes, while laboratory studies show materials such as activated carbon can remove certain contaminants like bromate. The pathway from cleaner exposure to longer life is plausible, but direct longevity trials are limited.

Who may benefit most, and in which settings?

Benefit is not distributed evenly. People with higher exposure burdens may have the most to gain from cleaner air and water. This includes urban residents near traffic or industry, workers with outdoor or combustion-related exposure, and people living in buildings with poor ventilation. In human housing research, inner-city children with asthma have been shown to face elevated indoor particulate matter (PM2.5, particles 2.5 micrometers or smaller; PM10, particles 10 micrometers or smaller) and allergen exposure, which may worsen respiratory burden.

Healthcare environments are another important setting. In a human observational study, dentistry clinics using aerosol-generating procedures had better Indoor Air Quality (IAQ) when mechanical ventilation and portable purifiers were operating. This finding is especially relevant for staff, patients, and trainees who spend many hours in enclosed spaces.

For water, communities near manufacturing sites, military installations, firefighting training areas, or contaminated aquifers may face greater per- and polyfluoroalkyl substances (PFAS) exposure. Available human evidence suggests special concern for children, because of vaccine-response findings, and for pregnant women, because some studies report associations with high blood pressure or pre-eclampsia. These are population-specific concerns, not universal outcomes.

When is this knowledge most important to apply?

This knowledge matters before obvious illness appears, because environmental exposure often acts gradually. A prevention-first view is common in the scientific literature: reducing pollutants at the source may lower cumulative exposure more reliably than depending only on downstream cleanup. That idea is especially relevant during home design, renovation, workplace planning, and community water management.

It is also important during higher-risk scenarios. Examples include wildfire smoke, heavy traffic exposure, flooding, mold-damaged buildings, aerosol-generating clinical procedures, and known water contamination events. After disasters, observational environmental studies have found severe contamination patterns, such as high mold indoors and bacterial contamination in surface water, showing that purification needs can shift quickly with context.

At the same time, early adoption should not be confused with blind faith in any device. Evidence differs by technology. Human studies often measure exposure markers, not lifespan. Laboratory studies of plasma treatment and activated carbon show pollutant removal potential, but some plasma systems also generate byproducts such as ozone, formaldehyde, and carbon monoxide (CO). In longevity terms, timing matters, but so does matching the method to the actual contaminant and evidence strength.

Tell Me More

How does purification interact with asthma, smoking, and daily indoor habits?

Air purification does not act in isolation. In human observational exposure research, smoking households had markedly higher particulate matter (PM2.5, particles 2.5 micrometers or smaller; PM10, particles 10 micrometers or smaller), showing that filtration may help but does not erase ongoing indoor sources. In a human randomized controlled trial in children with asthma, a home environmental program that included a High-Efficiency Particulate Air (HEPA) cleaner reduced particulate matter and cockroach allergen, and daytime symptoms were less frequent during the first 9 months. However, forced expiratory volume in 1 second (FEV1) and several other outcomes did not improve.

For longevity, the implication is indirect but reasonable: fewer repeated respiratory insults may support healthier aging, especially in people with airway disease. The caution is that symptoms, lung function, and long-term survival are not interchangeable outcomes. This trial had strong design features, yet adherence varied, which may have weakened the visible effect size. So, purification appears most relevant when combined with source control, such as reducing smoke and combustion exposure, rather than being treated as a stand-alone fix.

What do newer studies suggest about ventilation and filtration beyond comfort?

Recent work broadens the topic from comfort toward infection control and exposure management. In a human observational study from a dental clinic, mechanical ventilation kept carbon dioxide (CO2) generally within acceptable limits and portable purifiers mainly lowered fine particles and partly total volatile organic compounds (TVOC). These were measured environmental outcomes, not disease or longevity outcomes, so the connection to longer life comes from the broader evidence linking lower pollutant burden with better long-term health.

A separate mechanistic modeling study examined Heating, Ventilation and Air Conditioning (HVAC) filtration and estimated lower influenza risk across an 8-hour workday as filter efficiency increased, with Minimum Efficiency Reporting Value (MERV) 13 to 16 performing better than lower grades. Because this was a modeled study, it supports plausibility rather than proving real-world clinical benefit in every building. Still, it suggests that filtration strategy may matter for preserving health span by reducing repeated infectious stress, especially in crowded indoor settings.

What is commonly misunderstood about cleaner air and cleaner water?

A common misconception is that a purifier guarantees broad protection from all contaminants. The evidence does not support that. In the dental clinic study, air purifiers were described as an adjunct to ventilation, not a substitute. Carbon dioxide (CO2) can indicate whether fresh air exchange is adequate, but it does not measure every pollutant. Likewise, lower particulate matter (PM, airborne particles) does not automatically mean lower volatile chemicals or lower infection risk in every context.

Another misunderstanding is that removing a contaminant always translates into proven longevity benefit. For per- and polyfluoroalkyl substances (PFAS), human epidemiology suggests associations with some cancers, cholesterol changes, liver enzyme changes, reduced vaccine response in children, and pregnancy-related risks, but much of the toxicology base still comes from animal studies. That means the case for purification is partly built on exposure reduction and biological plausibility, not direct lifespan trials. In practical terms, purification is best viewed as one layer within a wider prevention strategy rather than a complete shield.

How might these findings reshape longevity-focused health strategies?

The evidence supports a shift from reacting to symptoms toward lowering cumulative exposure across settings. Low-quality policy and review evidence, together with human exposure and intervention studies, suggests that source reduction, ventilation, and targeted filtration may complement one another better than any single measure alone. This matters for longevity because chronic respiratory burden, infectious exposures, and persistent chemicals can interact with aging, cardiometabolic strain, and immune vulnerability over time.

Recent Per- and Polyfluoroalkyl Substances (PFAS) research also suggests that water safety strategies may need to move beyond drinking water alone, since exposure pathways can include multiple environmental media. The human evidence here remains incomplete because many studies are observational, sample sizes may be limited, and mixtures are difficult to study. Even so, the direction of research supports a more preventive model: reduce exposure early, monitor environments where burdens cluster, and interpret device performance separately from proven health outcomes. That approach is conservative, science-based, and aligned with protecting present function without assuming guaranteed lifespan gains.

Level Up

How do plasma-catalyst systems change pollutants?

Non-thermal plasma (NTP) works by giving energy to electrons rather than heating the whole gas. Those electrons generate reactive species such as hydroxyl radicals (OH) and ozone (O3), which can start oxidation or reduction reactions. In-plasma catalysis (IPC) adds a catalyst inside the discharge zone, so reactive species and the catalyst surface act together. In bench-scale laboratory air studies, this pairing improved removal of carbon monoxide (CO), nitrogen oxides (NOx), and toluene under selected conditions. One low-temperature CO experiment reported a synergy factor of 2, meaning the combined effect exceeded the sum of plasma alone and catalyst alone. That is a mechanistic engineering result, not a human health outcome.

For longevity, the main relevance is indirect. Cleaner air may reduce repeated exposure to gases that burden the lungs, blood vessels, and cellular stress pathways over time. But demonstrated human longevity benefit has not been measured in these plasma studies. The evidence here is laboratory-based, not in vivo human studies. It also has trade-offs. In one NOx plasma experiment, the primary outcome was conversion efficiency, with maximum removal reported under a factorial design using temperature, voltage, and propane-to-NOx ratio as variables. Secondary concerns included by-products such as ozone, formaldehyde, and carbon monoxide (CO), measured at low parts-per-million levels. That means mechanistic promise and real-world safety still need careful separation.

Why do reactor details matter so much?

Advanced purification systems often succeed or fail at the interface between chemistry and engineering. In the cycled storage-discharge (CSD) plasma catalytic process, pollutants are first stored on a catalyst, then oxidized during a discharge phase. This matters because residence time, oxygen access, catalyst order, and surface chemistry all shape what leaves the device. In a laboratory toluene study, the primary outcomes were carbon balance, carbon dioxide (CO2) selectivity, and breakthrough behavior. A layered design using hydrophobic hydrogen-form zeolite socony mobil-5 (HZSM-5) followed by silver-loaded hydrogen-form zeolite socony mobil-5 (Ag/HZSM-5) performed better than single-material layouts. Near-complete oxidation was reported only when stored toluene, gas flow, and silver loading were kept within a narrow range.

That level of tuning matters for longevity because incomplete treatment can create a false sense of safety. In the same evidence base, carbon monoxide (CO) could rise when the catalyst arrangement was less favorable, while ozone (O3) and nitrogen oxides (NOx) stayed low when catalytic consumption worked as intended. These are not trivial details. They shape whether a purifier mainly shifts pollutant form or actually lowers net toxic burden. The evidence is again in vitro or bench-scale, not in vivo human studies or in vivo animal studies. So the stronger claim is that reactor architecture influences exposure quality, which may matter for healthy aging if future real-world studies confirm durable reductions in harmful mixtures.

What makes persistent water pollutants hard to manage?

Per- and polyfluoroalkyl substances (PFAS) are difficult because persistence is built into their chemistry. Their carbon-fluorine structure resists breakdown, and their toxicokinetics, meaning absorption, distribution, metabolism, excretion, and clearance, differ across compounds. Human biomonitoring and epidemiologic studies suggest that some PFAS are associated with higher cholesterol, altered liver enzymes, reduced vaccine response in children, pregnancy-related blood pressure problems, and certain cancers. However, much of the mechanistic and hazard evidence still comes from in vivo animal studies, and the evidence varies by compound, dose, timing, and co-exposure pattern.

For longevity, this shifts the question from simple removal toward lifetime exposure management. Research overviews note that drinking water is only one pathway. Air, soil, food, and occupational settings may also contribute. That means future purification strategies may need to combine water treatment, surveillance, and better exposure mapping rather than relying on one household device category. The limitations are important. Available evidence includes small samples for some compounds, incomplete data for newer PFAS, methodological variation, and difficulty studying mixtures. Those limits may bias estimates in either direction, depending on which compounds were measured and how confounding was handled. So the present scientific position is cautious: reducing persistent exposure is reasonable, but the size of any eventual longevity benefit remains uncertain and likely depends on the specific PFAS profile and life stage.

Where may purification science be in a decade?

The likely direction is toward systems that are more selective, more monitored, and more preventive. Scientific sources already point to a shift from single-pollutant removal toward mixture-aware control. For air, that may mean pairing filtration, ventilation, and plasma-catalytic stages so one component captures particles while another degrades gases. For water, it may mean combining adsorption materials with stronger tracking of persistent chemicals such as per- and polyfluoroalkyl substances (PFAS). Life Cycle Assessment (LCA), which compares environmental burdens across a product’s full life span, may become more central because a purifier that removes one pollutant but uses high energy or generates harmful by-products may not improve long-term public health overall.

The evidence for this forecast is mixed. Human observational indoor air studies show that ventilation and portable purification can improve exposure markers such as particulate matter (PM) and carbon dioxide (CO2), but they do not yet measure aging biomarkers or survival. Laboratory studies show that catalyst design can suppress some by-products and improve energy yield, but scale-up may introduce new constraints. PFAS research frameworks also suggest the next decade will focus on mixtures, critical windows of exposure, and non-drinking-water pathways. From a longevity perspective, the field may move toward lower cumulative exposure across the life course, while remaining careful not to equate engineering performance with proven gains in life span or health span.

Pros and Cons

Pros

• Lower particle exposure
  ‍Human observational studies found ventilation plus portable purifiers lowered PM2.5 and PM10 in indoor settings. This may reduce repeated inhalation burden over time, which is relevant to respiratory and cardiovascular aging, especially in enclosed workplaces.

• Better ventilation status
  ‍In human indoor monitoring, mechanical ventilation kept CO2 mostly within accepted limits even during high occupancy. This supports more consistent air exchange, which may help limit pollutant buildup and preserve day-to-day function without implying direct lifespan proof.

• Symptom relief in asthma
  ‍In a human randomized trial, home environmental intervention with HEPA cleaning reduced indoor particles and cockroach allergen, with fewer daytime asthma symptoms over 6–12 months. Benefit appeared stronger for exposure and symptoms than for lung function outcomes.

• Targeted water cleanup
  ‍In vitro water-treatment studies found activated carbon can remove bromate, and thermal or alkaline modification increased adsorption capacity by about 10–22% versus unmodified material. This supports exposure reduction for a carcinogenic contaminant, not direct longevity outcomes.

• Supports prevention-first
  ‍Environmental and public health research consistently links lower pollution exposure with healthier ecosystems, worker productivity, and reduced chronic burden. For longevity, purification may add value when paired with source control rather than used as a stand-alone measure.

Cons

• By-product formation
  ‍Bench-scale plasma air treatment studies reported undesirable secondary pollutants, including ozone, formaldehyde, and carbon monoxide, around 1–5 ppm under tested conditions. This means pollutant conversion does not always equal cleaner net exposure.

• Costs can limit use
  ‍Environmental engineering papers note that membranes, nanocatalysts, and related modern control systems may face high capital or operating costs. This can reduce access and may shift resources away from source reduction or basic ventilation upgrades.

• Not a full substitute
  ‍Air purifiers improved particles more consistently than gases in human indoor studies, and water systems target only selected contaminants. Benefits depend on matching the device to the pollutant, so a single technology may leave major exposures unchanged.

• Performance can drop
  ‍In vitro activated-carbon studies found natural organic matter can block active sites and reduce bromate adsorption. This suggests real-world water chemistry may weaken removal efficiency compared with controlled laboratory conditions.

• Health gains not direct
  ‍Many purification studies measure exposure markers, engineering outputs, or adsorption capacity rather than disease events, aging biomarkers, or survival. As a result, direct longevity benefit is plausible but not established for most devices or materials.

Considerations

• Evidence varies by method
  ‍The evidence base spans human observational studies, one randomized home trial, laboratory adsorption studies, and bench-scale plasma experiments. Confidence is higher for exposure reduction than for long-term clinical or longevity outcomes.

• Exposure burden matters
  ‍People near traffic, industry, contaminated aquifers, or poorly ventilated buildings may have more to gain because baseline exposure is higher. Children, pregnant women, and workers in enclosed or polluted settings may merit distinct attention in the literature.

• Source control vs cleanup
  ‍Scientific literature often treats prevention at the source as different from downstream purification. Both may help, but they are not interchangeable, and cleanup alone may not offset ongoing smoke, combustion, or industrial emissions.

• PFAS gaps remain
  ‍Human and animal evidence links some PFAS with adverse health outcomes, but important gaps remain for newer compounds, mixtures, non-drinking-water pathways, and life-stage susceptibility. Longitudinal and confirmatory studies are still needed.

• System design matters
  ‍For plasma and catalytic systems, reactor layout, voltage, temperature, gas flow, and catalyst arrangement influenced removal and by-product formation in laboratory studies. Real-world benefit may depend as much on engineering details as on the core technology.

Actionable Intelligence

Innovative Tips

• CO2-Guided Purging
  ‍Human observational: test 10-min airing when CO2 rises; value for broad pollutants remains early.
  ‍
• Purifier Pulse Blocks
  ‍Human observational: run 30-60 min at peak occupancy; PM may fall, clinical benefit unclear.
  ‍
• Dual-Layer Filtration
  ‍Modeling+human data: pair HVAC filter with room unit for 8-hour use; outcome evidence is mixed.
  ‍
• ‍Busy-Room Zoning
  ‍Human observational: focus devices in 1 high-use room for 1-2 weeks; exposure gains may vary.
  ‍
• Event-Triggered Sealing
  ‍Observational: close windows for smoke events over 24-48 h; benefit depends on outdoor conditions.
  ‍
• Bromate-Specific Carbon
  ‍In vitro: carbon chemistry altered bromate uptake over test runs; household benefit not established.
  ‍
• PFAS-Risk Mapping
  ‍Public-health evidence: review local water data yearly; filters matter most in known risk zones.
  ‍
• Plasma With Byproduct Check
  ‍Bench study: plasma cut NOx in tests, yet 1-5 ppm byproducts appeared; real use remains early.
  ‍
• Ventilation Pattern Tests
  ‍Human observational: compare shifts for 1 week each; PM/TVOC may differ by occupancy pattern.
  ‍
• Source-First Audits
  ‍RCT+observational: track smoke/cooking sources for 7 days; cleanup alone may miss major burden.

Convergent and Divergent Viewpoints

Convergents

• Exposure reduction is the shared longevity link, not proven lifespan extension
  ‍Human observational, lab, and policy evidence agree cleaner air and water may lower long-term burden; direct lifespan outcomes were not measured in these studies.

• Ventilation improves indoor air markers in occupied settings
  ‍Human observational evidence found mechanical ventilation kept CO2 mostly below 1000 ppm and supported low PM in a high-occupancy clinic.

• Portable purifiers mainly reduce fine particles, with smaller effects on gases
  ‍Human observational evidence showed purifiers lowered PM2.5 most consistently and had more limited secondary effects on TVOC.

• Source control and prevention remain higher-level strategies than cleanup alone
  ‍Policy and epidemiologic evidence agree reducing pollution at the source may protect long-term health more reliably than downstream removal alone.

• Activated carbon can reduce bromate, but carbon chemistry strongly shapes performance
  ‍In vitro evidence found virgin carbon adsorbed bromate, while thermal or alkaline treatment improved capacity to about 20.3–22.5 mg/g.

• Acidic surface groups tend to weaken bromate adsorption
  ‍In vitro studies agree carbons with fewer acidic groups and suitable surface charge show better bromate uptake than oxidized variants.

• Plasma systems can remove combustion pollutants under tuned conditions
  ‍Bench-scale evidence found non-thermal plasma removed up to about 79% of NOx at selected settings; health benefit remains indirect.

• Plasma-catalyst pairing can outperform plasma alone in gas treatment
  ‍Laboratory evidence reported synergy in CO removal, including a synergy factor near 2, supporting combined reactor designs.

• PFAS exposure is a legitimate long-term health concern, though unevenly studied
  ‍Human observational plus animal evidence links some PFAS with cancer risk, cholesterol, liver, immune, and pregnancy-related effects.

• Evidence strength is stronger for exposure markers than for clinical aging outcomes
  ‍Across studies, measured endpoints were PM, CO2, TVOC, NOx conversion, or adsorption capacity, not survival, frailty, or aging biomarkers.

Divergent

• How much ventilation is enough for meaningful protection
  ‍Some researchers emphasize 6–7 ACH as adequate in busy clinics; others favor 10–12 ACH for faster infectious-air reduction.

• Whether portable purifiers add much when ventilation is already strong
  ‍Some say purifiers provide clear added PM2.5 reduction; others view benefit as modest when baseline IAQ and ventilation are already good.

• How to judge air quality: CO2 proxy versus multi-pollutant monitoring
  ‍Some researchers treat CO2 as a practical ventilation marker; others stress it misses PM, VOC, and byproduct exposure.

• Best plasma operating window for net benefit
  ‍Some favor higher voltage or temperature for greater conversion; others caution gains may plateau as energy use or byproducts rise.

• Whether plasma systems are ready for broad real-world deployment
  ‍Some view bench results as scalable with engineering refinement; others say fixed humidity, flow, and 100 ppm tests limit translation.

• Net value of plasma when secondary pollutants appear
  ‍Some argue low-level byproducts may be manageable; others say 1–5 ppm ozone, formaldehyde, and CO can offset part of the gain.

• Which activated-carbon modification is most practical outside the lab
  ‍Some favor thermal treatment for larger bromate gains; others prefer alkaline routes due to implementation or material trade-offs.

• How much lab adsorption data can guide public health decisions
  ‍Some say strong removal of carcinogenic bromate supports action; others note water chemistry, NOM, and scale-up may narrow real benefit.

• How broadly PFAS findings apply across compounds and life stages
  ‍Some researchers generalize concern to newer PFAS; others argue data remain too sparse across mixtures, exposure windows, and clearance rates.

• Whether purification should target single pollutants or mixed exposures
  ‍Some favor pollutant-specific devices for efficiency; others argue longevity needs mixture-aware systems because real exposures rarely occur alone.

Longevity Index

85/100

Definition

• Particulate Matter (PM2.5, PM10)
  ‍Airborne particles. PM2.5 are fine particles 2.5 micrometers or smaller, and PM10 are particles 10 micrometers or smaller.

• Volatile Organic Compounds (TVOC)
  ‍Total volatile organic compounds.

• Per- and Polyfluoroalkyl Substances (PFAS)
  ‍Persistent synthetic chemicals that can remain in water and the body for long periods.

• Bromate
  ‍A water contaminant of concern because it is carcinogenic.

• Indoor Air Quality (IAQ)
  ‍The condition of air inside buildings as it affects comfort and health.

• Mechanical ventilation
  ‍Replaces indoor air with cleaner air.

• Heating, Ventilation and Air Conditioning (HVAC)
  ‍Systems that move, filter, and condition indoor air.

• Air Changes per Hour (ACH)
  ‍Describes how often room air is replaced each hour.

• Carbon Dioxide (CO2)
  ‍Often used as an indicator of how well a space is ventilated, not as a full measure of all pollutants.

• High-Efficiency Particulate Air (HEPA) filters
  ‍Designed to capture very small airborne particles.

• Minimum Efficiency Reporting Value (MERV)
  ‍Rates how well many Heating, Ventilation and Air Conditioning (HVAC) filters remove particles across size ranges.

• Adsorption
  ‍Pollutants stick to a material surface, such as activated carbon.

• Activated carbon
  ‍A material surface used for adsorption in water treatment; laboratory studies show materials such as activated carbon can remove certain contaminants like bromate.

• Epidemiology / epidemiologic research
  ‍Human observational research that studies patterns of health outcomes and exposures in populations.

• Human biomonitoring
  ‍Measurement of chemicals or their markers in the human body to assess exposure.

• Toxicology
  ‍The study of harmful effects of chemicals on living organisms.

• In vivo
  ‍Studies performed in living humans or animals.

• In vitro
  ‍Studies performed outside a living organism, such as in laboratory systems.

• Mechanistic modeling study
  ‍A study that estimates how a system may behave based on modeled mechanisms rather than direct real-world clinical outcomes.

• Randomized controlled trial (RCT)
  ‍A study design in which participants are assigned to interventions by chance to test effects more rigorously.

• Forced Expiratory Volume in 1 second (FEV1)
  ‍A lung function measure showing how much air a person can forcefully exhale in one second.

• Aerosol-generating procedures
  ‍Clinical procedures that produce airborne particles or droplets.

• Allergen
  ‍A substance that can trigger allergic responses; in the context provided, cockroach allergen was measured indoors.

• Combustion gases
  ‍Gases produced by burning, discussed as air contaminants.

• Chronic respiratory burden
  ‍The long-term strain on the respiratory system from repeated exposures or disease.

• Cardiometabolic strain
  ‍Stress affecting cardiovascular and metabolic health over time.

• Health span
  ‍The period of life spent in good health.

• Longevity
  ‍Longer life or life span; in this context, often discussed indirectly through lower exposure rather than direct proof.

• Mortality
  ‍Death rates in a population.

• By-products
  ‍Secondary pollutants or compounds generated during treatment processes, such as ozone, formaldehyde, and carbon monoxide (CO).

• Ozone (O3)
  ‍A reactive gas that can be generated as a by-product in some plasma systems.

• Formaldehyde
  ‍A chemical by-product reported in some bench-scale plasma air treatment studies.

• Carbon Monoxide (CO)
  ‍A combustion-related gas and also a possible by-product in some plasma treatment systems.

• Nitrogen Oxides (NOx)
  ‍Combustion-related gases targeted in some plasma-catalyst air treatment studies.

• Toluene
  ‍A volatile chemical used as a target pollutant in laboratory air-treatment studies.

• Non-thermal plasma (NTP)
  ‍Works by giving energy to electrons rather than heating the whole gas.

• Reactive species
  ‍Chemically active molecules formed in plasma systems, such as hydroxyl radicals (OH) and ozone (O3), which can start oxidation or reduction reactions.

• Hydroxyl radicals (OH)
  ‍Reactive species generated in non-thermal plasma that can start oxidation or reduction reactions.

• Oxidation
  ‍A chemical reaction process started by reactive species in which pollutants are transformed.

• Reduction reactions
  ‍Chemical reactions that can be initiated by reactive species in plasma systems.

• In-plasma catalysis (IPC)
  ‍Adds a catalyst inside the discharge zone, so reactive species and the catalyst surface act together.

• Catalyst
  ‍A material that helps drive chemical reactions; in these studies it works together with plasma to improve pollutant removal.

• Discharge zone
  ‍The region inside a plasma system where the electrical discharge occurs.

• Synergy factor
  ‍A measure showing the combined effect exceeded the sum of plasma alone and catalyst alone.

• Factorial design
  ‍An experimental design using multiple variables such as temperature, voltage, and propane-to-NOx ratio.

• Parts per million (ppm)
  ‍A concentration unit used to report low levels of gases or by-products.

• Cycled storage-discharge (CSD) plasma catalytic process
  ‍A process in which pollutants are first stored on a catalyst, then oxidized during a discharge phase.

• Residence time
  ‍The time pollutants spend within a treatment system, affecting how well treatment works.

• Surface chemistry
  ‍The chemical properties of a material surface that influence adsorption or catalytic behavior.

• Carbon balance
  ‍A laboratory outcome measuring how carbon in a pollutant is distributed among products during treatment.

• Carbon dioxide (CO2) selectivity
  ‍A treatment outcome describing how much carbon is converted specifically into carbon dioxide.

• Breakthrough behavior
  ‍The point or pattern at which a pollutant begins to pass through a treatment material instead of being retained.

• Hydrophobic hydrogen-form zeolite socony mobil-5 (HZSM-5)
  ‍A zeolite material used in a layered plasma-catalytic design.

• Silver-loaded hydrogen-form zeolite socony mobil-5 (Ag/HZSM-5)
  ‍A silver-containing version of HZSM-5 used in layered catalyst layouts.

• Near-complete oxidation
  ‍A treatment result in which a pollutant is converted almost entirely through oxidation under narrow operating conditions.

• Aquifer
  ‍An underground water-bearing formation that can become contaminated.

• Toxicokinetics
  ‍Meaning absorption, distribution, metabolism, excretion, and clearance, differ across compounds.

• Confounding
  ‍A source of bias in observational research when other factors influence the observed association.

• Natural organic matter (NOM)
  ‍Material in real-world water chemistry that can block active sites and reduce bromate adsorption.

• Active sites
  ‍Reactive or adsorbing locations on a treatment material surface where contaminants are captured or transformed.

• Adsorption capacity
  ‍The amount of a contaminant a material can adsorb, often reported in milligrams per gram.

• Milligrams per gram (mg/g)
  ‍A unit used to report adsorption capacity of a treatment material.

• Surface charge
  ‍An electrical property of a material surface that can affect adsorption performance.

• Acidic surface groups
  ‍Surface chemical groups on activated carbon that tend to weaken bromate adsorption.

• Thermal modification
  ‍A treatment applied to activated carbon that increased bromate adsorption capacity in laboratory testing.

• Alkaline modification
  ‍A treatment applied to activated carbon that improved bromate adsorption in laboratory testing.

• Nitric-acid modification
  ‍A treatment applied to activated carbon that reduced bromate adsorption performance in laboratory testing.

• Life Cycle Assessment (LCA)
  ‍Compares environmental burdens across a product’s full life span.

• Mixture-aware control
  ‍An approach that targets combined real-world exposures rather than only single pollutants.

• Critical windows of exposure
  ‍Life stages or time periods when exposure may have stronger health effects.

• Biomarkers
  ‍Measured biological indicators; in this context, aging biomarkers or exposure markers were distinguished from survival outcomes.

• Biological plausibility
  ‍A judgment that a health effect is credible based on known biology, even without direct lifespan trials.

• Pre-eclampsia
  ‍A pregnancy-related complication mentioned as associated in some studies with PFAS exposure.

• Surveillance
  ‍Ongoing monitoring of environments or exposures to detect and manage risk.

• Exposure mapping
  ‍Tracking where and how exposures occur across settings or environmental media.

‍